Toxic epidermal necrolysis clinical guidelines

Journal of Burn Care and Research

Volumn 29, Issue 5, 2008, Pages 706-712

  Endorf, Frederick W ^a   Cancio, Leopoldo C ^a,b   Gibran, Nicole S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BIOBRANE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INFLIXIMAB; LUBRICATING AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SILVER; SILVER NITRATE;

CLINICAL EXAMINATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; ERYTHEMA MULTIFORME; EVIDENCE BASED PRACTICE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNITY; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGNOSIS; PUNCH BIOPSY; REVIEW; SCORING SYSTEM; SKIN BIOPSY; SKIN EXFOLIATION; STANDARD; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; WOUND DRESSING;

BURN UNITS; EPIDERMAL NECROLYSIS, TOXIC; FLUID THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 55249106206     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181848bb1     Document Type: Review

References (60)

1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-61.
2. Roujeau JC, Kelly JP, Rzany B, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
3. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998;102:1018-22.
4. Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006;155:422-8.
5. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-11.
6. Bastuji-Garin S, Rzany B, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
7. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002;23:87-96.
8. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97:272-80.
9. Werblowsky-Constantini N, Livshin R, Burstein M, Zeligowski A, Tur-Kaspa R. Toxic epidermal necrolysis associated with acute cholestatic viral hepatitis A. J Clin Gastroenterol 1989;11:691-3.
10. Correla O, Chosidow O, Saiag P, et al. Evolving patterns of drug-induced toxic epidermal necrolysis. Dermatology 1993;186:32-7.
11. Amon RB, Dimond RL. Toxic epidermal necrolysis. Rapid differentiation between staphylococcal and drug-induced disease. Arch Dermatol 1975;111:1433-7.
12. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 2005;141:683-7.
13. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
14. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003;139:39-43.
15. Imahara SD, Holmes JH, Heimbach DM, Engrav LE, Honari S, Klein MB, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006;27:270-5.
16. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890-2.
17. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272-6.
18. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008;29:141-6.
19. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.
20. Rabito SF, Sultana S, Konefal TS, Candido KD. Anesthetic management of toxic epidermal necrolysis: report of three adult cases. J Clin Anesth 2001;13:133-7.
21. Coss-Bu JA, Jefferson LS, Levy ML, Walding D, David Y, Klish WJ. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract 1997;12:81-4.
22. Windle EM. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis. J Hum Nutr Diet 2005;18:311-4.
23. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
24. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
25. Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 1999;20:406-10.
26. Bradley T, Brown RE, Kucan JO, Smoot EC HI, Hussman J. Toxic epidermal necrolysis: a review and report of the successful use of biobrane for early wound coverage. Ann Plast Surg 1995;35:124-32.
27. Bannasch H, Kontny U, Kruger M, Stark GB, Niemayer CM, Brandis M, et al. A semisynthetic bilaminar skin substitute used to treat pediatric full-body toxic epidermal necrolysis. Arch Dermatol 2004;140:160-2.
28. Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987;257:2171-5.
29. Birchall N, Langdon R, Cuono C, McGuire J. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 1987;16:368-72.
30. Pianigiani E, Ierardi F, Taddeucci P, et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg 2002;28:1173-6.
31. Prasad JK, Feller I, Thomson PD. Use of amnion for the treatment of Stevens-Johnson syndrome. J Trauma 1986;26:945-6.
32. Kelemen JJ III, Cioffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-8.
33. Asz J, Asz D, Moushey R, Seigel J, Mallory SB, Foglia RP. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006;41:E9-12.
34. Lehrer-Bell KA, Kirsner RS, Tallman PG, Kerdel FA. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate-impregnated dressings. Arch Dermatol 1998;134:877-9.
35. John T, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology 2002;109:351-60.
36. Kobayashi A, Yoshita T, Sugiyama K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology 2006;113:126-32.
37. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003;207:33-6.
38. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-9.
39. Meneux E, Wolenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998;91:283-7.
40. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997;18:520-4.
41. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.
42. Schlingman J, Mockenhaupt M, Fagot JP, Flahault A, Roujeau JC. Evaluation of treatment efficacy in a cohort of 281 patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) [abstract]. J Invest Dermatol 2004;123.
43. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporine A. J Trauma 2000;48:473-8.
44. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
45. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
46. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001;203: 45-9.
47. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-8.
48. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
49. Shorn R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-55.
50. Morici MV, Galen WK, Sherry AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000;27:2494-7.
51. Yip LW, Thong BY, Tan AW, Khin L-W, Cheng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005;19:846-53.
52. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005;58:504-10.
53. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36:218-21.
54. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-61.
55. Furubacke A, Berlin G, Anderson C, Sjoberg F. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999;25:1307-10.
56. Trent JT, Ma F, Kerdel F, et al. Dose of intraveneous immunoglobin and patient survival in SJS and toxic epidermal necrolysis. Exp Rev Derm 2007;5:299-303.
57. Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996;135:305-6.
58. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005;26:33-41
59. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006;27:26-33.
60. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infiximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146:707-9.